Target intelligence / Profile preview

BRISC and BRCA1-A complex member 2 (BABAM2)

Target
BABAM2
Molecular classification
Adapter protein (complex subunit), Scaffold protein (complex subunit), Other (component of DNA repair complexes)
01

Overview

BRISC and BRCA1-A complex member 2 (BABAM2) is a scaffold/adaptor protein integral to two large multi-protein complexes, BRCA1-A and BRISC, which participate in cell responses to DNA double-strand breaks. BABAM2 functions to stabilize these complexes and facilitate the removal of Lys63-linked ubiquitin chains at DNA damage sites, ensuring effective recruitment and regulation of BRCA1, cell cycle checkpoint activation, and maintenance of genomic stability. As part of the BRCA1-A complex, BABAM2 (also called BRE/BRCC45/MERIT40) interacts with tumor necrosis factor receptor-1 and acts as an anti-apoptotic protein. Genetic alterations in BABAM2 have been linked to altered breast cancer susceptibility, making it an important candidate for targeted research and possibly future therapeutics in cancers with DNA repair defects[1][2][3]. There are currently no known small-molecule or biologic drugs that directly target BABAM2, nor are there clinically established safety concerns specific to therapeutic targeting of BABAM2. However, its essential roles in DNA repair and apoptosis suggest that disruption can impact genome stability and cell viability.

Other names
BRCC45BREBRCC4MERIT40NBA1BRCA1/BRCA2-containing complex subunit 4BRCA1-A complex subunit BREBrain and reproductive organ-expressed proteinBrain and reproductive organ-expressed (TNFRSF1A modulator)
02

Biological functions

DNA damage responseDNA double-strand break repairCell cycle checkpoint controlApoptosis regulation (anti-apoptotic, death receptor-associated)Ubiquitination/deubiquitination (facilitator)
03

Disease associations

Cancer (particularly breast cancer susceptibility, DNA repair deficiency syndromes)
04

Safety considerations

Disruption can impact genome stability and cell viability
05

Biomarkers

Breast cancer risk (genetic variants associated with altered risk)

Beyond the preview

Go deeper on BRISC and BRCA1-A complex member 2 (BABAM2).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on BRISC and BRCA1-A complex member 2 (BABAM2).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call